Néoplasies myéloprolifératives – Partie 1 : survol du diagnostic et du traitement des NMP « classiques »

Sabrina Fowlkes, Cindy Murray, Adrienne Fulford, Tammy De Gelder, Nancy Siddiq

Abstract


Les néoplasies myéloprolifératives (NMP) sont des troubles rares, mais potentiellement mortels causés par la production excessive de cellules souches dans la moelle osseuse. Chez les patients atteints de NMP sans mutation du gène BCR-ABL1 (c.-à-d. la thrombocytémie essentielle [TE], la polycythémie vraie [PV] et la myélofibrose [MF], aussi appelées « NMP classiques »), les symptômes peuvent être incapacitants et nuire à la qualité de vie. Malgré tout, il est possible pour les patients souffrant de ces types de NMP de vivre plusieurs années, moyennant un traitement et un suivi à long terme. Les infirmières jouent donc un rôle essentiel pour favoriser la communication avec ces patients, évaluer leurs symptômes et leur enseigner les traitements et les stratégies d’autosoins pouvant les apaiser. Le présent article, premier d’une série de deux, propose aux infirmières et autres professionnels de la santé une revue du diagnostic et du traitement des NMP classiques les plus fréquentes. Le second article (aussi publié dans ce numéro) présentera aux infirmières des conseils pratiques pour traiter la symptomatologie associée aux NMP et ainsi améliorer la santé et le bien-être général des patients.


Full Text:

PDF

References


Abdel-Wahab, O.I., & Levine, R.L. (2009). Primary myelofibrosis: Update on definition, pathogenesis, and treatment. Annual Review of Medicine, 60, 233–45.

Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, … Vardiman, J.W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405.

Begna, K., Abdelatif, A., Schwager, S., Hanson, C., Pardanani, A., & Tefferi A. (2016). Busulfan for the treatment of myeloproliferative neoplasms: The Mayo Clinic experience. Blood Cancer Journal, 6, e427.

Birgegård, G. (2016). The use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia. Current Hematologic Malignancy Reports, 11(5), 348–355.

Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., … Tefferi, A. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113(13), 2895–2901.

Finazzi, G., & Barbui, T. (2007). How I treat patients with polycythemia vera. Blood, 109(12), 5104–11.

Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., … Tefferi, A. (2011). DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29(4), 392–397.

Geyer, H.L., & Mesa, R.A. (2014). Therapy for myeloproliferative neoplasms: When, which agent, and how? Blood, 124(24), 3529–37.

Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., … Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787–98.

Harrison, C.N., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Knoops, L., Cervantes, F., … Barbui, T. (2016). Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib versus best available therapy for myelofibrosis. Leukemia, 30, 1701–1707.

Mesa, R.A., & Cortes, J. (2013). Optimizing the management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. Journal of Hematology & Oncology, 6, 79.

Mesa, R., Jamieson, C., Bhatia, R., Deininger, M.W., Gerds, A.T., Gojo, I., Gotlib, J., … Sundar, H. (2016). Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 14(12), 1572–1611.

Nangalia, J., & Green, T.R. (2014) The evolving genomic landscape of myeloproliferative neoplasms. Hematology. American Society of Hematology. Education Program, 2014, 287–296.

Passamonti, F., Cervantes, F, Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., … Tefferi, A. (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115(9), 1703–1708.

Passamonti, F., Maffioli, M., Caramazza, D., & Cazzola M. (2011). Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget, 2(6), 485–490.

Passamonti, F., Vannucchi, A.M., Cervantes, F., Harrison, C., Morra, E., Kantarjian, H., & Verstovsek, S. (2015). Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia, 29(3), 739–40.

Radaelli, F., Onida, F., Rossi, F.G., Zilioli, V.R., Colombi, M., Usardi, P., Calori, R., & Zanella, A. (2008). Second malignancies in essential thrombocythemia (ET): A retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology, 13(4), 195–202.

Rollison, D.E., Howlader, N., Smith, M.T., Strom, S.S., Merritt, W.D., Ries, L.A., Edwards, B.K., & List, A.F. (2008). Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood, 112(1), 45–52.

Ruxolitinib (Jakavi) Product Monograph. Novartis Pharmaceuticals Canada, Inc. March 2, 2017.

Sirhan, S., Busque, L., Foltz, L., Grewal, K., Hamm, C., Laferriere, N., Laneuville, P., … Gupta, V. (2015). Evolving therapeutic options for polycythemia vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma & Leukemia, 15, 715–27.

Tefferi, A., & Barbui, T. (2015). Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. American Journal of Hematology, 90(2), 162–73.

Tefferi, A., & Barbui, T. (2017). Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 92(1), 94–108.

Tefferi, A., & Pardanani, A. (2015). Myeloproliferative neoplasms: a contemporary review. JAMA Oncology, 1(1), 97–105.

Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A.M., Rodeghiero, F., Randi, M.L., … Barbui, T. (2013). Survival and prognosis among 1,545 patients with contemporary polycythemia vera: an international study. Leukemia, 27(9), 1874–1881.

Tonkin, J., Francis, Y., Pattinson, A., Peters, T., Taylor, M., Thompson, R., & Wallis, L. (2012). Myeloproliferative neoplasms: Diagnosis, management and treatment. Nursing Standard, 26(51), 44–51.

Vannucchi, A.M., Kiladjian, J,J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., … Verstovsek, S. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(5), 426–435.

Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., … Kantarjian, H.M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366(9), 799–807.

Verstovsek, S., Vannucchi, A.M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., … Kiladjian, J.J. (2016). Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 101(7), 821–9.

Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R., & Tefferi, A. (2006). Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81(2), 159–66.


Refbacks

  • There are currently no refbacks.